uniQure Q2 FY26 net loss more than doubles to $81.06 million; revenue rises 9.5% to $5.84 million
QURE•Q2 FY26 results and pipeline update
- uniQure posted a GAAP net loss of USD 81.1 million, or USD 1.22 per share, in Q2 2026, widening from a year earlier.
- Revenue rose 9.96% to USD 5.8 million, driven by higher license revenue.
- R&D expenses fell 3.95% to USD 34 million, while SG&A expenses climbed 28.89% to USD 17.4 million.
- Cash, cash equivalents and current investment securities totaled USD 810.3 million at June 30, 2026; a USD 259 million follow-on extended runway into 2030.
- AMT-130 BLA submission for Huntington's disease remains on track for Q3 2026; topline four-year Phase I/II data expected September 2026.
